Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis

Ping Yang, Hengheng Zhang, Jinming Li, Zitao Li, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Jiuda Zhao, GuoShuang Shen, Yi Zhao · 2024

Read Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis by Ping Yang, Hengheng Zhang, Jinming Li, Zitao Li, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Jiuda Zhao, GuoShuang Shen, Yi Zhao (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11656431.txt.

Description

Ping Yang and nine colleagues pooled clinical trial data on liver toxicity from antibody-drug conjugates used in breast cancer. These targeted drugs deliver chemotherapy straight to cancer cells, but the liver still takes damage. The systematic review searched three databases through March twenty twenty-three. Liver enzyme elevations were the main measure. Incidence was combined across trials with meta-analysis, and drugs were compared against each other.

Overall rates of liver injury were high. Sacituzumab govitecan produced the highest rate of one enzyme's elevation, about twenty-five percent. Trastuzumab deruxtecan led for a second enzyme, at about thirty-two percent. Grades of severity were separated in the analysis. The twenty twenty-four ranking helps oncologists anticipate which conjugate needs the closest liver monitoring in breast cancer patients.

Catalog record

CREATORPing Yang, Hengheng Zhang, Jinming Li, Zitao Li, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Jiuda Zhao, GuoShuang Shen, Yi Zhao
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11656431

Browse the full library · About the Tower of Babel